4:07 PM
 | 
Apr 16, 2018
 |  BC Extra  |  Clinical News

Merck rises, BMS falls on PD-1 combo data for NSCLC

Merck & Co. Inc. (NYSE:MRK) and Bristol-Myers Squibb Co. (NYSE:BMY) both reported detailed data Monday from Phase III trials of their anti-PD-1 mAb combos to treat advanced non-small cell lung cancer in the first-line setting.

Merck gained $1.48 to $58.65 after its Keytruda pembrolizumab combo showed an overall survival (OS) benefit in patients with non-squamous disease across three PD-L1 subpopulations. BMS lost $4.57 to $54.08 on data showing that its Opdivo nivolumab plus anti-CTLA-4 mAb Yervoy ipilimumab improved progression-free survival (PFS) in patients with high tumor mutation burden (TMB) across two PD-L1 subgroups.

Both companies presented data at the American Association for Cancer Research meeting in Chicago and published them in the New England Journal of Medicine.

Merck's KEYNOTE-189 trial enrolled 616 non-squamous NSCLC patients regardless of PD-L1 expression, with no EGFR or anaplastic lymphoma kinase (ALK)...

Read the full 663 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >